BioPharmSignal logoBioPharmSignal

Biotech News

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

Alvotech (ALVO)AlvotechEarnings

REYKJAVIK, ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the nine months and third quarter ended September 30, 2026 on Wednesday, November 11, 2026, after the U.S. market close.

Related news

ALVOAlvotech2026-08-19 20:30 EST

Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update

ALVOAlvotech2026-08-10 12:00 EST

Alvotech to Report Financial Results for H1 2026

ADMAADMA Biologics2026-10-28 11:00 EST

ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026

CHRSCoherus BioSciences, Inc.2026-10-26 13:30 EST

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

ADMAADMA Biologics2026-07-29 11:00 EST

ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026

CHRSCoherus BioSciences, Inc.2026-07-22 17:36 EST

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

PHARPharming Group2026-07-16 06:00 EST

Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

ANIPANI Pharmaceuticals2026-11-05 11:51 EST

ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results

AMRXAmneal Pharmaceuticals2026-11-03 11:00 EST

Amneal Reports Third Quarter 2026 Financial Results

RXRXRecursion2026-11-02 21:30 EST

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

View all latest news

Alvotech

Global Biosimilar Developer and Manufacturer Alvotech is a biotechnology company focused exclusively on developing and manufacturing biosimilar medicines. It operates an integrated model covering cell-line development, process development, clinical studies, regulatory submissions, commercial-scale manufacturing, and supply to regional...

Recent company news

ALVOAlvotech2026-11-02 12:00 EST

Alvotech to Present at Upcoming Investor Conferences in November

ALVOAlvotech2026-10-28 11:00 EST

Alvotech birtir uppgjör fyrstu níu mánaða ársins 2026 þann 11. nóvember nk.

ALVOAlvotech2026-10-28 11:00 EST

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

ALVOAlvotech2026-10-20 08:30 EST

Lyfjastofnun Bandaríkjanna samþykkir nýja framleiðsluaðferð Alvotech sem rúmlega tvöfaldar afköst við framleiðslu á Simlandi

ALVOAlvotech2026-10-14 08:30 EST

Alvotech og Advanz Pharma fyrst til að sækja um markaðsleyfi fyrir hliðstæðu við augnlyfið Eylea í háum styrk

Stock data

Close
4.55 USD
Market cap
936.14M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States